Kadmon is a pharmaceutical company based in New York, New York, specializing in the development and commercialization of innovative therapies. Located at 450 E 29th St, Kadmon focuses on advancing treatments that address complex medical conditions, primarily within the fields of immunology, fibrosis, and oncology. The company’s operations in the heart of New York City position it at the crossroads of cutting-edge research and a vibrant healthcare ecosystem.
The company’s approach integrates scientific research with clinical development to bring new pharmaceutical solutions to patients in need. Kadmon works closely with healthcare professionals and researchers to identify promising compounds and advance them through the necessary regulatory pathways. This commitment to rigorous development practices ensures that their therapies meet the highest standards of safety and efficacy.
Kadmon’s presence in New York allows it to leverage a network of academic institutions, medical centers, and industry partners, fostering collaboration that supports innovation. The company’s efforts contribute to expanding treatment options and improving patient outcomes in various therapeutic areas. With a focus on both research and practical application, Kadmon plays a significant role in the pharmaceutical landscape of the region.
As a pharmaceutical company, Kadmon emphasizes the importance of ongoing research and development to address unmet medical needs. Its strategic location and specialized focus enable it to remain responsive to advancements in medicine and technology. Through continued dedication to scientific exploration, Kadmon strives to impact the healthcare community positively and support the well-being of patients locally and beyond.


































